ModeRNA, Stealth Startup Backed By Flagship, Unveils New Way to Make Stem Cells

Xconomy Boston — 

ModeRNA Therapeutics, a new startup out of Cambridge, MA-based Flagship VentureLabs, announced it has developed a method for producing human induced pluripotent stem cells, which are embryonic-like stem cells that are formed by reprogramming adult stem cells. Flagship and three other scientists co-founded the startup this summer with an undisclosed amount of Series A funding, as first reported by Dow Jones VentureWire this morning.

The research team behind ModeRNA, based out of Children’s Hospital Boston and led by Derrick Rossi, said the stem cells formed with the new method could be used to create an array of cells that can be useful in medicine—such as blood cells, neurons, and muscle cells. Rossi, who is also connected to the Harvard Stem Cell Institute, started ModeRNA alongside Kenneth Chien, who leads the Massachusetts General Hospital Cardiovascular Research Center, and MIT biochemist Robert Langer, according to VentureWire. The startup is backed by Flagship and one another undisclosed investor, Flagship general partner Doug Cole told me on a phone call this morning.

ModeRNA’s research team developed synthetic, chemically modified RNA that can incite cells to reprogram, while avoiding detection by cells’ anti-viral defense systems, which typically target messenger RNA (mRNA) involved in reprogramming cells to function like embryonic stem cells, according to the announcement. The researchers published their study online last Thursday in the journal Cell Stem Cell.

San Diego-based Fate Therapeutics is also working on technology to spur adult cells into functioning like embryonic stem cells, for use in the pharmaceutical field. The ModeRNA research team says that its modified RNA technology could be useful in regenerative therapies, by helping to incite the formation of muscle cells, or in boosting cell’s production of certain proteins, to treat diseases such as cystic fibrosis.

The company isn’t saying much about its specific plans for commercializing its modified RNA technology. But Cole said, “It’s generated a lot of excitement in the marketplace.”

By posting a comment, you agree to our terms and conditions.

12 responses to “ModeRNA, Stealth Startup Backed By Flagship, Unveils New Way to Make Stem Cells”

  1. Mark says:

    NOt sure why Moderna had not been sued by U Penn? Moderna is clearly encroching the U Penn and Yamanaka at Koyoto University IP.

  2. Evan says:

    They will get sued down the road. Maybe not by U Penn. Cell Script is the IP assignee. They may go after them if IP is violated.

  3. Juliet says:

    who says they haven’t already been sued? this company won’t even make it to 2013. boat is sinking–bad management, all the brains are leaving the company.

  4. john says:

    they have recently recruited very good talent. I joined recently and was very impressed by how fast they generated great data.

    • David says:

      huh? Good talent? Maybe they recruited you which you consider a good talent. Read the review at Glassdoor, and your will know the good talent from CEO, CSO and down… a bunch of guys who are perfect at arrogance and data manipulation.

  5. Tara says:

    hi john, I am glad you are enjoying your time at moderna. I hope things improve there for your sake, however I heard that 10 people left the company in less than a year….not sure what means.

  6. Steve says:

    I’m not sure where they’re recruiting people from since most candidates won’t go to this company after hearing so many people have resigned or been fired and the company is considered to be a classic example of bad management. Also not sure what a benchmark for great data is when I heard all their data comes from CROs and not in house-this company isn’t doing anything special. P.S. Recently joined=soon to be fired. Good Luck!

    • David says:

      Yeah, and CSO who knows no science? Maybe they are producing data at the CEO and CSO backyard. This is a junkyard company, managed by bunch of arrogant, inefficient, and as mentioned on Glassdoor data manipulator.